-
公开(公告)号:US20220088178A1
公开(公告)日:2022-03-24
申请号:US17489106
申请日:2021-09-29
Inventor: Tsafrir S. Leket-Mor , Bertram Jacobs , Lydia Meador , Karen Kibler
IPC: A61K39/21
Abstract: Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
-
2.
公开(公告)号:US20240226273A1
公开(公告)日:2024-07-11
申请号:US18283042
申请日:2022-03-30
Inventor: Bertram Jacobs , Karen Kibler
IPC: A61K39/215 , A61K39/00 , A61P31/14 , C12N15/86
CPC classification number: A61K39/215 , A61P31/14 , C12N15/86 , A61K2039/5256 , A61K2039/543 , C12N2710/24143 , C12N2770/20022 , C12N2770/20034 , C12N2840/105 , C12N2840/206
Abstract: Recombinant poxvirus expressing severe acute respiratory syndrome coronavirus 2 structural proteins and virus-like particles are described, along with methods of making and using the same.
-
公开(公告)号:US11918642B2
公开(公告)日:2024-03-05
申请号:US17489106
申请日:2021-09-29
Inventor: Tsafrir S. Leket-Mor , Bertram Jacobs , Lydia Meador , Karen Kibler
CPC classification number: A61K39/21 , A61K2039/5258 , A61K2039/575 , C07K14/161 , C07K14/162 , C12N2740/16034 , C12N2740/16134 , C12N2740/16234
Abstract: Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
-
公开(公告)号:US20190328864A1
公开(公告)日:2019-10-31
申请号:US16396676
申请日:2019-04-27
Inventor: Tsafrir Mor , Bertram Jacobs , Lydia Meador , Karen Kibler
IPC: A61K39/21
Abstract: Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.
-
公开(公告)号:US20190183947A1
公开(公告)日:2019-06-20
申请号:US16304564
申请日:2017-05-25
Inventor: Bertram Jacobs , Heather Koehler , William Arndt , Karen Kibler , Kelly Trainor , Chandra Mitnik , Jeffrey Langland
IPC: A61K35/768 , A61P35/00 , A61K9/00
CPC classification number: A61K35/768 , A61K9/0019 , A61K45/06 , A61P35/00 , C12N7/00 , C12N2710/24121 , C12N2710/24122 , C12N2710/24132
Abstract: Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.
-
-
-
-